Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases.
Publication
, Journal Article
Nash, RA; Dansey, R; Storek, J; Sullivan, KM; Pavletic, S; McDonagh, KT; Kraft, GH; Mayes, MD; Forman, SJ; Holmberg, LA; McSweeney, PA
Published in: BLOOD
November 16, 2000
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2000
Volume
96
Issue
11
Start / End Page
406A / 406A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Nash, R. A., Dansey, R., Storek, J., Sullivan, K. M., Pavletic, S., McDonagh, K. T., … McSweeney, P. A. (2000). Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases. BLOOD, 96(11), 406A-406A.
Nash, R. A., R. Dansey, J. Storek, K. M. Sullivan, S. Pavletic, K. T. McDonagh, G. H. Kraft, et al. “Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases.” BLOOD 96, no. 11 (November 16, 2000): 406A-406A.
Nash RA, Dansey R, Storek J, Sullivan KM, Pavletic S, McDonagh KT, et al. Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases. BLOOD. 2000 Nov 16;96(11):406A-406A.
Nash, R. A., et al. “Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases.” BLOOD, vol. 96, no. 11, AMER SOC HEMATOLOGY, Nov. 2000, pp. 406A-406A.
Nash RA, Dansey R, Storek J, Sullivan KM, Pavletic S, McDonagh KT, Kraft GH, Mayes MD, Forman SJ, Holmberg LA, McSweeney PA. Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases. BLOOD. AMER SOC HEMATOLOGY; 2000 Nov 16;96(11):406A-406A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2000
Volume
96
Issue
11
Start / End Page
406A / 406A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology